CULLINAN THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
CULLINAN THERAPEUTICS, INC. (CGEM) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 18.98 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 21.33M shares, a 9.14% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 19.55M shares, a 13.95% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 17.15M shares, a 19.53% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 14.35M shares, a 42.57% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 21.06M shares, a 33.62% increase from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 15.76M shares, a 0.32% increase from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 15.71M shares, a 228471.43% increase from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.87K shares, a 26.47% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 18.98M shares 10-Q · filed 2026-08-06 | |||||||
| 2026-03-31 | 21.33M shares 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | 21.06M shares 10-K · filed 2026-03-10 | |||||||
| 2025-09-30 | 20.97M shares 10-Q · filed 2025-11-06 | |||||||
| 2025-06-30 | 20.70M shares 10-Q · filed 2026-08-06 | |||||||
| 2025-03-31 | 19.55M shares 10-Q · filed 2026-05-07 | |||||||
| 2024-12-31 | 15.76M shares 10-K · filed 2026-03-10 | |||||||
| 2024-09-30 | 15.22M shares 10-Q · filed 2025-11-06 | |||||||
| 2024-06-30 | 15.07M shares 10-Q · filed 2025-08-07 | |||||||
| 2024-03-31 | 17.15M shares 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | 15.71M shares 10-K · filed 2025-02-27 | 15.71K shares 10-K · filed 2024-03-14 | ||||||
| 2023-09-30 | 15.54M shares 10-Q · filed 2024-11-07 | |||||||
| 2023-06-30 | 15.14M shares 10-Q · filed 2024-08-08 | |||||||
| 2023-03-31 | 14.35M shares 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | 6.87K shares 10-K · filed 2024-03-14 | |||||||
| 2022-09-30 | 6.68M shares 10-Q · filed 2023-11-08 | 6.68 shares 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | 6.25M shares 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | 10.07M shares 10-Q · filed 2023-05-11 | 10.07M shares 10-Q · filed 2022-05-16 | ||||||
| 2021-12-31 | 9.35K shares 10-K · filed 2023-03-09 | 9.35M shares 10-K · filed 2022-03-17 | ||||||
| 2021-09-30 | 7.33 shares 10-Q · filed 2022-11-14 | 7.33M shares 10-Q · filed 2021-11-09 | ||||||
| 2021-06-30 | 7.13M shares 10-Q · filed 2022-08-10 | 7.13M shares 10-Q · filed 2021-08-10 | ||||||
| 2021-03-31 | 6.85M shares 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | 4.97M shares 10-K · filed 2022-03-17 | |||||||
| 2020-09-30 | 274.36K shares 10-Q · filed 2021-11-09 | |||||||
| 2020-06-30 | 376.32K shares 10-Q · filed 2021-08-10 | |||||||
| 2020-03-31 | 478.29K shares 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |